Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-center, Randomized, Active-controlled, Parallel-group, Open-label, Phase I Study to Evaluate Safety and Immunogenicity of Single Injection of LBVD or Eupenta Co-administered With Imovax Polio in Healthy Adults

NCT03208101 is registered in ClinicalTrials.gov with LG Chem as lead sponsor.

NCT NCT03208101
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03208101 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-center, Randomized, Active-controlled, Parallel-group, Open-label, Phase I Study to Evaluate Safety and Immunogenicity of Single Injection of LBVD or Eupenta Co-administered With Imovax Polio in Healthy Adults
Lead sponsor
LG Chem
Phase
Phase 1
Overall status
Completed
Start date
July 3, 2017
Completion date
December 21, 2017
Enrollment
42 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diphtheria, haemophilus influenzae type b infection, hepatitis b, pertussis, poliomyelitis, tetanus